Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616 · see citing works

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889 · see citing works

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · see citing works

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543 · see citing works

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977 · see citing works

Adaptive immunity to SARS-CoV-2 and COVID-19

Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860 · see citing works

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747 · see citing works

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257 · see citing works

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939 · see citing works

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021

Campbell, F., Archer, B. N., Laurenson‐Schafer, H., Jinnai, Y., Konings, F. A. J., Batra, N., Pavlin, B. I., Vandemaele, K., Kerkhove, M. D. V., Jombart, T., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.24.2100509 · Cited by 792 · see citing works

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00628-0 · Cited by 603 · see citing works

SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients

Geers, D., Shamier, M. C., Bogers, S., den Hartog, G., Gommers, L., Nieuwkoop, N. N., Schmitz, K. S., Rijsbergen, L. C., van Osch, J. A. T., Dijkhuizen, E., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj1750 · Cited by 529 · see citing works

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Wall, E. C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01290-3 · Cited by 491 · see citing works

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Nutalai, R., Tuekprakhon, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.033 · Cited by 460 · see citing works

Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India

Dhar, M. S., Marwal, R., Radhakrishnan, V., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., et al. (2021) · doi:10.1101/2021.06.02.21258076 · Cited by 296 · see citing works

Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays

Bewley, K. R., Coombes, N. S., Gagnon, L., McInroy, L., Baker, N., Shaik, I., St-Jean, J. R., St-Amant, N., Buttigieg, K. R., Humphries, H. E., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00536-y · Cited by 293 · see citing works

The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials

Serres, G. D., Skowronski, D. M., Wu, X., & Ambrose, C. S. (2013) · Eurosurveillance · doi:10.2807/1560-7917.es2013.18.37.20585 · Cited by 247 · see citing works

High throughput detection and genetic epidemiology of SARS-CoV-2 using COVIDSeq next-generation sequencing

Bhoyar, R. C., Jain, A. K., Sehgal, P., Divakar, M. K., Sharma, D., Imran, M., Jolly, B., Ranjan, G., Rophina, M., Sharma, S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247115 · Cited by 146 · see citing works

Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2

Low, J. S., Vaqueirinho, D., Mele, F., Foglierini, M., Jerak, J., Perotti, M., Jarrossay, D., Jovic, S., Perez, L. H., Cacciatore, R., et al. (2021) · Science · doi:10.1126/science.abg8985 · Cited by 131 · see citing works

Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1

Yadav, P., Sapkal, G., Abraham, P., et al. (2021) · bioRxiv · doi:10.1101/2021.05.12.443645 · Cited by 45

Development of a Fast SARS-CoV-2 IgG ELISA, Based on Receptor-Binding Domain, and Its Comparative Evaluation Using Temporally Segregated Samples From RT-PCR Positive Individuals

Mehdi, F., Chattopadhyay, S., Thiruvengadam, R., Sarla, Y., Kumar, M., Sinha, S. K., Goswami, S., Kshetrapal, P., Wadhwa, N., Natchu, U. C. M., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.618097 · Cited by 42 · see citing works

India’s COVID-vaccine woes — by the numbers

Padma, T. V. (2021) · Nature · doi:10.1038/d41586-021-00996-y · Cited by 38 · see citing works

Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model

Shrivastava, T., Singh, B., Rizvi, Z. A., Verma, R., Goswami, S., Vishwakarma, P., Jakhar, K., Sonar, S., Mani, S., Bhattacharyya, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641447 · Cited by 28 · see citing works

What should define a SARS-CoV-2 “breakthrough” infection?

Schieffelin, J. S., Norton, E. B., & Kolls, J. K. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151186 · Cited by 21 · see citing works

Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis

Zeng, B., Gao, L., Zhou, Q., Yu, K., & Sun, F. (2022) · BMC Medicine · doi:10.1186/s12916-022-02397-y · Cited by 267 · see citing works

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 216 · see citing works

Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials

Yang, Z.-R., Jiang, Y.-W., Li, F.-X., Liu, D., Lin, T.-F., Zhao, Z.-Y., Wei, C., Jin, Q.-Y., Li, X.-M., Jia, Y.-X., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00390-1 · Cited by 138 · see citing works

Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern

Vikkurthi, R., Ansari, A., Pai, A. R., Jha, S. N., Sachan, S., Pandit, S., Nikam, B., Kalia, A., Jit, B. P., Parray, H. A., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01161-5 · Cited by 59 · see citing works

Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months

Medigeshi, G., Batra, G., Murugesan, D. R., Thiruvengadam, R., Chattopadhyay, S., Das, B., Gosain, M., Ayushi, Singh, J., Anbalagan, A., et al. (2022) · medRxiv · doi:10.1016/j.ebiom.2022.103938 · Cited by 57 · see citing works

Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice

Gao, F., Wu, R., Shen, M., Huang, J., Li, T., Hu, C., Luo, F., Song, S., Mu, S., Hao, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105479 · Cited by 54 · see citing works

Will the COVID-19 pandemic end with the Delta and Omicron variants?

Wang, C., & Han, J. (2022) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01369-7 · Cited by 52 · see citing works

Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity

Khatri, R., Siddqui, G., Sadhu, S., Maithil, V., Vishwakarma, P., Lohiya, B., Goswami, A., Ahmed, S., Awasthi, A., & Samal, S. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00760-7 · Cited by 55 · see citing works

Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants

Liu, Y., Wang, Z., Zhuang, X., Zhang, S., Chen, Z., Zou, Y., Sheng, J., Li, T., Tai, W., Yu, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37926-7 · Cited by 42 · see citing works

COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective

Marcelin, J. R., Pettifor, A. E., Janes, H., Brown, E. R., Kublin, J. G., & Stephenson, K. E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac124 · Cited by 38 · see citing works

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

Lv, J., Wu, H., Xu, J., & Liu, J. (2022) · Infectious Diseases of Poverty · doi:10.1186/s40249-022-00977-x · Cited by 39 · see citing works

A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines

He, X., Su, J., Ma, Y., Zhang, W., & Tang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945930 · Cited by 40 · see citing works

Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England

(2022) · doi:10.1038/s41467-022-35168-7 · Cited by 37 · see citing works

IL-9 aggravates SARS-CoV-2 infection and exacerbates associated airway inflammation

Sadhu, S., Dalal, R., Dandotiya, J., Binayke, A., Singh, V., Tripathy, M. R., Das, V., Goswami, S., Kumar, S., Rizvi, Z. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39815-5 · Cited by 35 · see citing works

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Sobieszczyk, M. E., Maaske, J., Falsey, A. R., Sproule, S., Robb, M. L., Frenck, R. W., Tieu, H., Mayer, K. H., Corey, L., Neuzil, K. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160565 · Cited by 33 · see citing works

Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis

Wang, K., Wang, L., Li, M., Xie, B., He, L., Wang, M., Zhang, R., Hou, N., Zhang, Y., & Jia, F. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.820544 · Cited by 33 · see citing works

Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021

Xu, K., Fan, C., Han, Y., Dai, L., & Gao, G. F. (2022) · International Immunology · doi:10.1093/intimm/dxac031 · Cited by 31 · see citing works

Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults

Rakshit, S., Adiga, V., Ahmed, A., Parthiban, C., Kumar, N. C., Dwarkanath, P., Shivalingaiah, S., Rao, S., D′Souza, G., Dias, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.985938 · Cited by 31 · see citing works

Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study

Bouillon, K., Baricault, B., Botton, J., Jabagi, M.-J., Bertrand, M., Semenzato, L., Le Vu, S., Drouin, J., Dray-Spira, R., Weill, A., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000104 · Cited by 31 · see citing works

A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation

Binayke, A., Zaheer, A., Vishwakarma, S., Singh, S., Sharma, P., Chandwaskar, R., Gosain, M., Raghavan, S., Murugesan, D. R., Kshetrapal, P., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00794-9 · Cited by 28 · see citing works

A data-driven interpretable ensemble framework based on tree models for forecasting the occurrence of COVID-19 in the USA

Zheng, H.-L., An, S.-Y., Qiao, B., Guan, P., Huang, D., & Wu, W. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-23132-3 · Cited by 27 · see citing works

The Vaccine World of COVID-19: India’s Contribution

Chavda, V. P., Vihol, D. R., Solanki, H. K., & Apostolopoulos, V. (2022) · Vaccines · doi:10.3390/vaccines10111943 · Cited by 26 · see citing works

SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines

Sunagar, R., Singh, A., & Kumar, S. (2023) · Vaccines · doi:10.3390/vaccines11040849 · Cited by 28 · see citing works

Clinical and experimental evidence suggest omicron variant of SARS-CoV-2 is inherently less pathogenic than delta variant independent of previous immunity

Thiruvengadam, R., Rizvi, Z. A., Raghavan, S., Murugesan, D. R., Gosain, M., Dandotiya, J., Ayushi, A., Samal, S., Pandey, A. K., Wadhwa, N., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01373-3 · Cited by 24 · see citing works

Attributed causes of excess mortality during the COVID-19 pandemic in a south Indian city

Lewnard, J. A., B, C. M., Kang, G., & Laxminarayan, R. (2023) · Nature Communications · doi:10.1038/s41467-023-39322-7 · Cited by 23 · see citing works

A Comprehensive Analysis of Structural and Functional Changes Induced by SARS-CoV-2 Spike Protein Mutations

Mushebenge, A. G.-A., Ugbaja, S. C., Mbatha, N. A., Khan, R. B., & Kumalo, H. M. (2023) · COVID · doi:10.3390/covid3090100 · Cited by 22 · see citing works

Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination

Das, S. R., Singh, J., Shaman, H., Singh, B., Anantharaj, A., Patil, S., Pandey, R., Lodha, R., Pandey, A. K., & Medigeshi, G. R. (2022) · Nature Communications · doi:10.1038/s41467-022-31170-1 · Cited by 21 · see citing works

Comparison of the Test-negative Design and Cohort Design With Explicit Target Trial Emulation for Evaluating COVID-19 Vaccine Effectiveness

Li, G., Gerlovin, H., Muñiz, M. J. F., Wise, J. K., Madenci, A. L., Robins, J. M., Aslan, M., Cho, K., Gaziano, J. M., Lipsitch, M., et al. (2023) · Epidemiology · doi:10.1097/ede.0000000000001709 · Cited by 21 · see citing works

Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative studies: a systematic review and meta-analysis

Tsang, T. K., Sullivan, S. G., Huang, X., Wang, C., Wang, Y., Nealon, J., Yang, B., Ainslie, K. E. C., & Cowling, B. J. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae142 · Cited by 20 · see citing works

Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections

Mani, S., Kaur, A., Jakhar, K., Kumari, G., Sonar, S., Kumar, A., Das, S., Kumar, S., Kumar, V., Kundu, R., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125444 · Cited by 16 · see citing works

Test negative design for vaccine effectiveness estimation in the context of the COVID-19 pandemic: A systematic methodology review

Mésidor, M., Liu, Y., Talbot, D. C., Skowronski, D. M., Serres, G. D., Merckx, J., Koushik, A., Tadrous, M., Carazo, S., Jiang, C., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.013 · Cited by 16 · see citing works

Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis

Contractor, A., Shivaprakash, S., Tiwari, A. A., Setia, M. S., & Gianchandani, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276759 · Cited by 15 · see citing works

COVID-19 vaccines: Update of the vaccines in use and under development

Marta, R. A., Nakamura, G. E. K., Aquino, B. D. M., & Bignardi, P. R. (2022) · Vacunas · doi:10.1016/j.vacun.2022.06.003 · Cited by 16 · see citing works

Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study

Yuan, Y., Xu, J., Ma, B., Chen, G., Wang, Z., Wang, S., Nan, J., Zhang, J., Wang, B., Yan, W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107866 · Cited by 15 · see citing works

Potential biases in test-negative design studies of COVID-19 vaccine effectiveness arising from the inclusion of asymptomatic individuals

Ortíz‐Brizuela, E., Carabalí, M., Jiang, C., Merckx, J., Talbot, D. C., & Schnitzer, M. E. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae288 · Cited by 14 · see citing works

A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant

Hingankar, N. K., Deshpande, S., Das, P., Rizvi, Z. A., Wibmer, C. K., Mashilo, P., Ansari, M. Y., Burns, A., Barman, S., Zhao, F.-Z., et al. (2021) · bioRxiv · doi:10.1371/journal.ppat.1010465 · Cited by 13 · see citing works

Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19

Binayke, A., Zaheer, A., Dandotiya, J., Gupta, S. K., Mani, S., Tripathy, M. R., Madan, U., Shrivastava, T., Kumar, Y., Pandey, A. K., et al. (2022) · Vaccines · doi:10.3390/vaccines10101762 · Cited by 12 · see citing works

A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern

Parray, H. A., Narayanan, N., Garg, S., Rizvi, Z. A., Shrivastava, T., Kushwaha, S., Singh, J., Murugavelu, P., Anantharaj, A., Mehdi, F., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010994 · Cited by 12 · see citing works

Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELDTM and COVAXIN® induced immunity in COVID-19 exposed Indians

Rakshit, S., Babji, S., Parthiban, C., Madhavan, R., Adiga, V., Sharon Eveline, J., Kumar, N. C., Ahmed, A., Shivalingaiah, S., Shashikumar, N., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00731-w · Cited by 12 · see citing works

Priority age targets for COVID-19 vaccination in Ethiopia under limited vaccine supply

Galli, M., Zardini, A., Gamshie, W. N., Santini, S., Tsegaye, A., Trentini, F., Marziano, V., Guzzetta, G., Manica, M., d’Andrea, V., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-32501-y · Cited by 11 · see citing works

Covishield vaccine induces robust immune responses in Bangladeshi adults

Bhuiyan, T. R., Akhtar, M., Khaton, F., Rahman, S. I. A., Ferdous, J., Alamgir, A. S. M., Rahman, M., Kawser, Z., Hasan, I., Calderwood, S. B., et al. (2022) · IJID Regions · doi:10.1016/j.ijregi.2022.04.006 · Cited by 10 · see citing works

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021

Murali, S., Sakthivel, M., Kamaraj, P., Venkatasamy, V., Thangaraj, J. W. V., Shete, A. M., Varghese, A. J., Arjun, J., Kumar, C. P. G., Yadav, P. D., et al. (2022) · Vaccines · doi:10.3390/vaccines10060970 · Cited by 10 · see citing works

Vaccinating against a Novel Pathogen: A Critical Review of COVID-19 Vaccine Effectiveness Evidence

Black, B. S., & Thaw, D. B. (2023) · Microorganisms · doi:10.3390/microorganisms12010089 · Cited by 9 · see citing works

Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India

Selvavinayagam, T. S., Anavarathan, S., Selvam, J. M., Sampath, P., Vijayalakshmi, V., Kumar, C. A. B., Subramaniam, S., Parthipan, K., Raju, S., Avudaiselvi, R., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-50338-3 · Cited by 9 · see citing works

Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis

Aviraj, K. S., Wasnik, A., Gupta, L., Ranjan, A., & Suresh, H. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02856-6 · Cited by 8 · see citing works

A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

Kulkarni, P. S., Gunale, B., Kohli, S., Lalwani, S. K., Tripathy, S. P., Kar, S., Raut, S. K., Kulkarni, P., Apte, A. A., Bavdekar, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-43578-w · Cited by 8 · see citing works

Comparative T and B immune responses of four different anti-COVID-19 vaccine strategies 6 months after vaccination

Bonnet, B., Chabrolles, H., Archimbaud, C., Brebion, A., Godignon, M., Dutheil, F., Lambert, C., Cosme, J., Mirand, A., Ollier, A., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.03.006 · Cited by 7 · see citing works

BCG revaccination qualitatively and quantitatively enhances SARS-CoV-2 spike-specific neutralizing antibody and T cell responses induced by the COVISHIELDTM vaccine in SARS-CoV-2 seronegative young Indian adultsPreprint

Rakshit, S., Adiga, V., Ahmed, A., Parthiban, C., Kumar, N. C., Shivalingaiah, S., Rao, S., D′Souza, G., Dwarkanath, P., Dias, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1395683/v1 · Cited by 7 · see citing works

COVID-19 vaccines in the age of the delta variant

Wheatley, A., & Juno, J. (2021) · Lancet. Infectious Diseases (Print) · doi:10.1016/s1473-3099(21)00688-5 · Cited by 19 · see citing works

COVID-19 vaccine hesitancy in inflammatory arthritis patients: serial surveys from a large longitudinal national Australian cohort

McMaster, C., Liew, D. F. L., Lester, S. E., Rischin, A., Black, R. J., Chand, V., Fletcher, A., Lassere, M. N., MARCH, L. M., Robinson, P. C., et al. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac503 · Cited by 6 · see citing works

SEI3R2D2V: Pandemic Modeling and Analysis of Its Latent Factors: A Case Study of COVID-19 in India

Kansal, V., & Pandey, P. K. (2022) · IEEE Transactions on Computational Social Systems · doi:10.1109/tcss.2022.3225639 · Cited by 5 · see citing works

Humoral and cellular immune response in patients of liver cirrhosis and immunocompetent recipient of ChAdOx1nCoV-19 Vaccine (Covishield)

Dandu, H. R., Goel, A., Kumar, M., Malhotra, H. S., Katiyar, H., Agarwal, M., Kumar, N., Pandey, P., Rani, S., & Yadav, G. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01258-z · Cited by 5 · see citing works

A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine

Dold, C., Oguti, B., Silva-Reyes, L., Stanzelova, A., Raymond, M., Smith, C. C., Moore, M., Barton, A. L., Choi, E. M.-L., Plested, E. L., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn1441 · Cited by 4 · see citing works

Characterization of immune responses to two and three doses of the adenoviral vectored vaccine ChAdOx1 nCov-19 and the whole virion inactivated vaccine BBV152 in a mix-and-match study in India

Chaudhary, A., Madhavan, R., Babji, S., Raju, R., Syed, C., Kumar, A., Saravanan, P., Nikitha, O. S., Xavier, J. V. L., Chelladurai, J. S. D., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.059 · Cited by 4 · see citing works

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India – Authors' reply

Thiruvengadam, R., Awasthi, A., Bhatnagar, S., & Garg, P. K. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00120-7 · Cited by 4 · see citing works

Correlation of severity & clinical outcomes of COVID-19 with virus variants: A prospective, multicentre hospital network study

Wadhwa, K., Malik, S. D., Balaji, S., Thiruvengadam, R., Bashyam, M. D., Bhattacharya, P. K., Behera, B., Bhardwaj, P., Biswas, N. K., Das, A., et al. (2024) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_1041_23 · Cited by 3 · see citing works

Cell-Mediated Immunity (CMI) for SARS-CoV-2 Infection Among the General Population of North India: A Cross-Sectional Analysis From a Sub-sample of a Large Sero-Epidemiological Study

Misra, P., Garg, P. K., Awasthi, A., Kant, S., Rai, S. K., Ahmad, M., Guleria, R., Deori, T. J., Mandal, S., Jaiswal, A., et al. (2023) · Cureus · doi:10.7759/cureus.48824 · Cited by 3 · see citing works

Understanding the landscape of the SARS‐CoV‐2‐specific T cells post‐omicron surge

Binayke, A., Zaheer, A., Vishwakarma, S., Sharma, P., Dandotiya, J., Raghavan, S., Gosain, M., Singh, S., Chattopadhyay, S., Kaushal, J., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29877 · Cited by 3 · see citing works

Dispelling the Myth of a Pandemic of the Unvaccinated

McLeod, D., Martins, I., Pelech, S., Beck, C., & Shaw, C. A. (2022) · International Journal of Vaccine Theory Practice and Research · doi:10.56098/ijvtpr.v2i1.38 · Cited by 2 · see citing works

SARS-CoV-2 variants’-Alpha, Delta, and Omicron D614G and P681R/H mutations impact virus entry, fusion, and infectivityPreprint

Khatri, R., Siddqui, G., Sadhu, S., Maithil, V., Vishwakarma, P., Lohiya, B., Goswami, A., Ahmed, S., Awasthi, A., & Samal, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1310197/v1 · Cited by 3 · see citing works

A broadly neutralising monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV2 variant of concernsPreprint

Kumar, R., Parray, H. A., Narayan, N., Garg, S., Rizvi, Z. A., Shrivastava, T., Kushwaha, S., Singh, J., Murugavelu, P., Anantharaj, A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1431974/v1 · Cited by 3 · see citing works

COVID‐19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial Evidence on the Omicron Variant)Preprint

Black, B. S., & Thaw, D. B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4155493 · Cited by 3 · see citing works

Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11410-7 · Cited by 2 · see citing works

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world

Garg, P. K., & Thiruvengadam, R. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00207-9 · Cited by 2 · see citing works

Augmenting Vaccine Efficacy against Delta Variant with ‘Mycobacterium-w’-Mediated Modulation of NK-ADCC and TLR-MYD88 Pathways

Jaiswal, S. R., Saifullah, A., Arunachalam, J., Lakhchaura, R., Tailor, D., Mehta, A., Bhagawati, G., Aiyer, H., Biswas, S., Khamar, B. M., et al. (2023) · Vaccines · doi:10.3390/vaccines11020328 · Cited by 2 · see citing works

Proinflammatory innate cytokines and metabolomic signatures shape the T cell response in active COVID-19Preprint

Binayke, A., Zaheer, A., Dandotiya, J., Gupta, S. K., Mani, S., Tripathi, M., Madan, U., Shrivastava, T., Kumar, Y., Pandey, A. K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.11.483930 · Cited by 2 · see citing works

COVID-19 vaccines effectiveness against SARS-CO-V-2 infection among persons attending RT-PCR centre at a Medical College Hospital in Telangana: A case control studyPreprint

Veerapu, N., Inmdar, D. P., Kumar, B. P. R., Basavaraju, A., Guddanti, P., Issapuri, S. D., Ganta, N. S., & Gopi, A. (2022) · medRxiv · doi:10.1101/2022.05.15.22273945 · Cited by 2 · see citing works

Exploring socio-psychological drivers of nuclear power acceptance in Jordan: A machine learning approach

Alhawamdeh, A. S., Novendah, I., & Prasetyo, Y. T. (2026) · Nuclear Engineering and Technology · doi:10.1016/j.net.2026.104339 · Cited by 1 · see citing works

In Silico Analysis Predicts a Limited Impact of SARS-CoV-2 Variants on CD8 T Cell Recognition

Isaeva, O. I., Ketelaars, S. L. C., & Kvistborg, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.891524 · Cited by 1 · see citing works

Detection of SARS-CoV-2 Delta Variant of Concern AY.57 and Clinical Characteristics of Imported Cases on a Vietnamese Coal Carrier Vessel in East Kalimantan, Indonesia: A Case Report

Marwan, M., Winardi, W., Mu'ti, A., Wahyuni, S., Jatmiko, R. W., Alfian, D. I., Nur, M. I., & Sewu, S. (2022) · Jurnal Respirasi · doi:10.20473/jr.v8-i.2.2022.99-105 · Cited by 1 · see citing works

Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Infection among Persons Attending the RT-PCR Center at a Medical College Hospital in Telangana: A Case- Control Study

Veerapu, N., Inamdar, D. P., Kumar, B. P. R., Basavaraju, A., Guddanti, P., Issapuri, S. D., Ganta, N. S., & Gopi, A. (2022) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_273_22 · Cited by 1 · see citing works

Comparison of Risk Factors During First and Second Wave of COVID-19 in Patients with Autoimmune Rheumatic Diseases (AIRD): Results from KRACC Subset

Jain, V. K., Shobha, V., Kumar, S., Janardana, R., & Selvam, S. (2023) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.20230827.co · Cited by 1 · see citing works

CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters

Dandotiya, J., Adhikari, N., Tripathy, M. R., Jakhar, K., Sonar, S., Pati, D. R., Kanchan, V., Prasad, V. S., Kumar, J., Senapati, N. K., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447962 · Cited by 1 · see citing works

A randomised, double-blind, placebo-controlled evaluation of polyphenol-based standardised cinnamon bark extract in patients with mild-to-moderate COVID-19

Thakurdesai, P. A., Deshpande, P., Bhaskaran, S., & Raje, D. (2025) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2025.101023 · Cited by 1 · see citing works

Long-term Durable Humoral Immune Response to Heterologous Antigenic Exposure Post six months by Natural SARS-CoV-2 Infection and VaccinationPreprint

Batra, G., Murugesan, D. R., Chattopadhyay, S., Mehdi, F., Ayushi, A., Gosain, M., Singh, S., Das, S. J., Deshpande, S., Bhattacharya, J., et al. (2022) · medRxiv · doi:10.1101/2022.02.23.22271381 · Cited by 1 · see citing works

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India

Chakrabarti, S., Chakrabarti, S. S., Chandan, G., Kaur, U., & Agrawal, B. K. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00132-3 · Cited by 1 · see citing works

SARS-CoV-2 and its variants, but not Omicron, induces severe thymic atrophy and impaired T cell developmentPreprint

Rizvi, Z. A., Sadhu, S., Dandotiya, J., Binayke, A., Sharma, P., Singha, V., Das, V., Khatri, R., Kumar, R., Samal, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1581769/v1 · Cited by 1 · see citing works

A randomized, controlled study to evaluate the safety and immunogenicity of a heterologous booster dose of an adjuvanted SARS CoV-2 recombinant spike protein vaccine in adultsPreprint

Kulkarni, P. S., Gunale, B., Kohli, S., Lalwani, S. K., Tripathy, S. P., Kar, S., Raut, S. K., Kulkarni, P., Apte, A. A., Bavdekar, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2549560/v1 · Cited by 1 · see citing works

Effectiveness of SARS‐CoV‐2 vaccines used in Malaysia: A systematic review and meta‐analysisPreprint

Thantry, A. D. K., Lakshmanan, P. A. P., Kunasakaran, D. A. L., & Shenq, E. C. (2023) · Research Square · doi:10.21203/rs.3.rs-2888103/v1 · Cited by 1 · see citing works

Approaches for estimating COVID-19 vaccine effectiveness using observational data in administrative databases: a systematic reviewPreprint

Chow, J. Y., Goh, Z. J., Li, R., Lim, D. Z. Y., Wee, L. E., Lye, D. C., Tan, K. B., & Lim, J. T. (2025) · medRxiv · doi:10.1101/2025.09.29.25336864 · Cited by 1 · see citing works

Effect Of Stress on Cellular Properties of Enterococcus Faecium

Rabenreither (2009) · Scientia Pharmaceutica · doi:10.3797/scipharm.oephg.21.po-31

Obowiązek szczepień przeciw COVID-19: skuteczne narzędzie walki z pandemią czy bezpodstawny sanitaryzm?

Witczak, P. (2022) · Wydawnictwo Naukowe Instytutu na rzecz Kultury Prawnej Ordo Iuris eBooks · doi:10.37873/oipress.37.43

Spectrum of SARSCOV2 infection with the efficacy of Covaxin and Covishield vaccines during third wave of COVID-19 pandemic: an experience of a densest state of India

Saha, R. (2022) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20222872

COVID-19 vaccines: Update of the vaccines in use and under development

Marta, R. A., Nakamura, G. E. K., Aquino, B. D. M., & Bignardi, P. R. (2022) · Vacunas (English Edition) · doi:10.1016/j.vacune.2022.11.007

COVID Vaccines vs. Viral Evolution: Who Will Win the Battle?

Sharma, S., Sood, V., & Sharma, D. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230328172918

Evaluation of COVID-19 vaccine effectiveness in different high-risk facility types during a period of Delta variant dominance in the Republic of Korea: a cross-sectional study

Lee, M. J., Hwang, M.-J., Kim, D. S., Park, S. K., Choi, J., Lee, J. J., Kim, J.-M., Kim, Y., Park, Y.-J., Gwack, J., et al. (2023) · Osong Public Health and Research Perspectives · doi:10.24171/j.phrp.2023.0188

Estimating COVID-19 vaccine protection rates via dynamic epidemiological models—a study of 10 countries

Zhu, Y., Gu, J., Qiu, Y., & Chen, S. X. (2023) · The Annals of Applied Statistics · doi:10.1214/23-aoas1764 · Cited by 1 · see citing works

Effectiveness of the chAdOx1 nCoV-19 vaccine in preventing COVID-19 infection

Sarwat, T., Singh, D. K., Singh, N. P., Singh, S. P., & Kakru, D. K. (2022) · Indian Journal of Allergy Asthma and Immunology · doi:10.4103/ijaai.ijaai_19_22

COVID-19 grave en el contexto de una población vacunada: Estudio de casos y controles

Muñoz, I. D., Medina-Gómez, O. S., & Julian-Bello, G. I. (2024) · Revista de Epidemiologia e Controle de Infecção · doi:10.17058/reci.v14i1.19005

Multipronged strategy for protection and motivation of healthcare workers during the COVID-19 pandemic: a real-life study

Premkumar, M., Dutta, U., Sandhu, A., Kaur, H. P., Singh, M. P., Goyal, K., Guru, R. R., Lakshmi, P. V. M., Gupta, M., Biswal, M., et al. (2024) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2023.459

Safety Surveillance of Covishield Vaccine-Associated Adverse Events During the COVID-19 Pandemic: A Retrospective Longitudinal Study

Chaudhary, S., Aggarwal, M., Kumari, P., Vishwas, G., Meshram, G. G., Dhaka, R., & Garg, M. (2024) · Cureus · doi:10.7759/cureus.67257

Vaccine Research and Development in India for COVID-19 and Influenza

Kanjo, K., Ghadiyaram, C., & Varadarajan, R. (2024) · Springer eBooks · doi:10.1007/978-981-97-0896-3_6

Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults

Capão, A., de Araújo, M. F., Tort, L. F. L., Toledo, T. S., de Oliveira, A. C. A., Caetano, B. C., Resende, P. C., Martins‐Filho, O. A., Alves, M. R., Grifoni, A., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126785

Assessing Effectiveness of COVID-19 Vaccine in India Through SE${}^{\textbf{2}}$I${}^{\textbf{6}}$R${}^{\textbf{4}}$D${}^{\textbf{4}}$V CompartmentalModel Using a Cohort Study

Kansal, V., & Pandey, P. K. (2025) · IEEE Transactions on Computational Social Systems · doi:10.1109/tcss.2025.3552579

Evaluation of the Humoral Immune Response Following Two Doses of a Coronavirus Disease 2019 Vector-Based Vaccine During the Initial Rollout in Bangladesh

Sultana, S., Rahman, M. H., Taher, A., Islam, M. N., Islam, S. R. U., & Nessa, A. (2025) · Cureus · doi:10.7759/cureus.99882

Access to Healthcare in Rural Jordan: Challenges Faced by Nurses and Innovative Solutions - A Narrative Review

Ashour, A., Hani, S. B., & Eyadat, A. M. (2026) · The Open Nursing Journal · doi:10.2174/0118744346411092251104103405

Cellular Immune Responses are Preserved and May Contribute to Chadox1 ChAdOx1 nCoV-19 Vaccine Effectiveness Against Infection Due to SARS-CoV-2 B·1·617·2 Delta Variant Despite Reduced Virus NeutralisationPreprint

Thiruvengadam, R., Awasthi, A., Medigeshi, G. R., Bhattacharya, S., Mani, S., Sivasubbu, S., Srivatsava, T., Samal, S., Murugesan, D. R., Desiraju, B. K., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3884946 · Cited by 8 · see citing works

Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study

Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11410-7 · Cited by 2 · see citing works

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India

Chakrabarti, S., Chakrabarti, S. S., Chandan, G., Kaur, U., & Agrawal, B. K. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00132-3 · Cited by 1 · see citing works

Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India – Authors' reply

Thiruvengadam, R., Awasthi, A., Bhatnagar, S., & Garg, P. K. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00120-7 · Cited by 4 · see citing works

ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections

Satwik, R., Satwik, A., Katoch, S., & Saluja, S. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.08.005 · Cited by 25 · see citing works